Car-t cell therapy for solid tumors with gd2 or cd70 markers
Part of Cancer clinical trials.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack tumors with specific markers (GD2 or CD70). It may be an option for patients whose cancer has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a tumor that has not responded to standard treatment, has spread, or has come back.
- Your tumor must show certain markers (GD2 or CD70) when tested by your doctor.
- You are between 1 and 75 years old and weigh at least 22 pounds (10 kg).
- Your doctor expects you to live at least 8 more weeks.
- You must have had a break from certain cancer treatments: at least 7 days for biologics or targeted drugs, 4 weeks for monoclonal antibodies, and 1 week for radiation.
- Your heart, lungs, liver, kidneys, and blood counts must be within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy called CAR-T cells that are designed to find and attack cancer cells that have a specific marker (GD2 or PSMA). It is for people whose cancer has not been controlled by standard treatment, and it aims to see if this therapy is safe and effective.
This study tests a special immune cell treatment (CAR T cells) that targets a marker called GD2 on solid tumor cells. It is for people whose cancer has not responded to standard treatments or has come back.
This trial tests a special type of cell therapy called CAR T cells. The cells are changed in the lab to find and attack a protein called CD276 on the surface of solid tumors. If the treatment works, your own immune cells could shrink the tumor or slow its growth.
This trial tests a new type of immune therapy (CAR T-cells) that is engineered to find and attack neuroblastoma cells by targeting specific markers (GD2, PSMA, and CD276) on the cancer cells. It is for patients whose cancer has not responded to standard treatments and who are healthy enough to receive this experimental cell therapy.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests a personalized cell therapy that uses your own immune cells, modified to better find and attack lymphoma cells. It may help when standard treatments have not worked.
Hear when a new Cancer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.